The emerging therapeutic landscape of relapsed/refractory multiple myeloma Benjamin TanenbaumTimothy MiettShyam A. Patel Review Article 03 December 2022 Pages: 1 - 11
Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives H. Miles PrinceMartin HutchingsRanjana Advani Review Article Open access 13 December 2022 Pages: 13 - 29
Comparison of multiple treatments in the management of transplant-related thrombotic microangiopathy: a network meta-analysis Jingyi YangXiaoyan XuYue Han Review Article 22 December 2022 Pages: 31 - 39
Excess deaths among adults with sickle cell disease in 2020 compared to prior years Susanna CurtisBillett HennyMinniti Caterina Original Article 10 November 2022 Pages: 41 - 44
Chronic active Epstein-Barr virus infection involving gastrointestinal tract with hemophagocytic lymphohistiocytosis Kai ShenXiao ShuaiHongbing Ma Original Article 19 December 2022 Pages: 45 - 53
Comparison of clinical characteristics of first-episode thrombotic thrombocytopenic purpura and TTP-like syndrome: a retrospective cohort study in a level I hematology center in China Guiying DongFang-e ShiJihong Zhu Original Article 17 November 2022 Pages: 55 - 62
A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy Andrew F. BerdelRaphael KochChristoph Schliemann Original Article Open access 18 November 2022 Pages: 63 - 72
Integrated single-cell transcriptome analysis of CD34 + enriched leukemic stem cells revealed intra- and inter-patient transcriptional heterogeneity in pediatric acute myeloid leukemia Deepshi ThakralVivek Kumar SinghRachna Seth Original Article 17 December 2022 Pages: 73 - 87
Cytogenetic evolution predicts a poor prognosis in acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation Ruiqi LiZiwei WangJianmin Wang Original Article 21 December 2022 Pages: 89 - 97
Monocytosis at the time of diagnosis has a negative prognostic impact in myelodysplastic syndromes with less than 5% bone marrow blasts A. KasprzakC. AssadiU. Germing Original Article Open access 21 November 2022 Pages: 99 - 106
Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic Ales ObrKaterina BenesovaPavel Klener Original Article Open access 11 November 2022 Pages: 107 - 115
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience Susanne GhandiliDzenefa AlihodzicLisa B. Leypoldt Original Article Open access 16 November 2022 Pages: 117 - 124
Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma Limei ZhangShuzhao ChenYun Wang Original Article Open access 28 November 2022 Pages: 125 - 132
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey Mehmet Sinan DalBahar Uncu UluTülin Fırat Tuğlular Original Article 19 November 2022 Pages: 133 - 140
Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience Lauren D. CurryReinhold MunkerMaxwell M. Krem Original Article 11 November 2022 Pages: 141 - 154
Comparing the efficacy of salvage regimens for relapsed/refractory B-cell acute lymphoblastic leukaemia: a systematic review and network meta-analysis Han-Yu CaoChao-Ling WanSheng-Li Xue Original Article 17 November 2022 Pages: 155 - 165
Bortezomib-based chemotherapy for patients with Waldenström macroglobulinemia: a single-center experience Ziou LiuShenghua JiangXin Cao Original Article 14 November 2022 Pages: 167 - 174
Refractory hepatosplenic T-cell lymphoma was successfully treated with salvage allogeneic hematopoietic stem cell transplantation combined with enhanced myeloablative preconditioning Wenqiu HuangSong XueJingbo Wang Original Article 10 November 2022 Pages: 175 - 180
Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation Shahram MoriMengni GuoJuan Carlos Varela Original Article 03 December 2022 Pages: 181 - 190
Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysis Jorge Garcia BorregaBoris BöllJan-Michel Heger Original Article Open access 17 November 2022 Pages: 191 - 197
Feasibility of electronic patient-reported outcome monitoring and self-management program in aplastic anemia and paroxysmal nocturnal hemoglobinuria—a pilot study (ePRO-AA-PNH) Silas BänzigerKimmo WeisshaarBeatrice Drexler Original Article Open access 03 November 2022 Pages: 199 - 208
Remission of universal vitiligo after allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome Yingying ZhaiQingyuan WangSong Jin Letter to the Editor 15 November 2022 Pages: 209 - 210
Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms Bahga KatameshAhmad NanaaAref Al-Kali Letter to the Editor 04 November 2022 Pages: 211 - 212
Feasibility of autologous peripheral blood stem cell mobilization and harvest in adult patients with FLT3-mutated acute myeloid leukemia receiving chemotherapy combined with midostaurin: a single-center experience Stefano CordellaAngelica ParisottoFabio Forghieri Letter to the Editor 20 October 2022 Pages: 213 - 217
Impact of tablet crushing on the dissolution of venetoclax Takeo YasuEri HikitaMikio Shirota Letter to the Editor 04 November 2022 Pages: 219 - 220
Escalation to high‐flow nasal cannula oxygen in hematological malignancy: the right choice at the right moment? Pasquale BuonannoGiuseppe ServilloAntonio Matias Esquinas Letter to the Editor 09 November 2022 Pages: 221 - 222
Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma Kohei ShinmuraSo OkuboTomonori Nakazato Letter to the Editor 17 November 2022 Pages: 223 - 225
A neonatal case of congenital blastic plasmacytoid dendritic cell neoplasm with KMT2C gene duplication Jian LiJun WangYongjun Fang Letter to the Editor 09 November 2022 Pages: 227 - 229
CD19 CAR T-cell infusion during severe COVID-19 acute respiratory distress syndrome in large B-cell lymphoma Nina BuchtelePhilipp WohlfarthPhilipp B. Staber Letter to the Editor 18 November 2022 Pages: 231 - 234
New-onset Evans syndrome in a patient with SLE post SARS-CoV2 mRNA vaccination Timothy Y. M. NgWinnie Z. Y. TeoGim Gee Teng Letter to the Editor 12 November 2022 Pages: 235 - 236
Platelet recovery with ibrutinib therapy in patient with treatment-refractory immune thrombocytopenia Paul Christopher ParishDonald C. MooreRichard Cambareri Letter to the Editor 28 November 2022 Pages: 237 - 238
Mutations in the plasma cell clone identify mechanism of polyneuropathy in a case of POEMS syndrome associated with Castleman disease and multiple myeloma Annamaria BrioliAntje WyrwaKarin G. Schrenk Letter to the Editor Open access 19 November 2022 Pages: 239 - 242
Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma Yosuke MasamotoArika ShimuraMineo Kurokawa Letter to the Editor 11 November 2022 Pages: 243 - 244
Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab Tim StrüßmannJohannes JungReinhard Marks Letter to the Editor Open access 17 November 2022 Pages: 245 - 247
